Law.com Subscribers SAVE 30%

Call 855-808-4530 or email [email protected] to receive your discount on a new subscription.

Home Topics

Regulation

Features

Anti-Money Laundering Enforcement Update Image

Anti-Money Laundering Enforcement Update

Kyle R. Freeny & Benjamin G. Greenberg

Over the last decade or so, anti-money laundering (AML), counter-terrorism financing (CFT), and sanctions compliance have been the subject of increased enforcement efforts. We expect this trend to accelerate in 2021 and beyond, propelled at least in part by the recent enactment of the Anti-Money Laundering Act of 2020.

Features

NY Court Rewrites Rules On Liquidated Damages In Surrender Agreements Image

NY Court Rewrites Rules On Liquidated Damages In Surrender Agreements

Adam Leitman Bailey & Dov Treiman

In a recent decision, the NY Court of Appeals handed down a decision with a new interpretation of the law of liquidated damages with regard to surrender agreements. Trustees of Columbia v. D'Agostino rewrites the rules of when a tenant simply gives up on the space.

Features

Drawing the Line Between Real Property and Personal Property In the UCC Image

Drawing the Line Between Real Property and Personal Property In the UCC

Barbara M. Goodstein

The back-and-forth is certainly confusing, but what is clear is that it can be unclear exactly where the line between real property and personal property should be drawn.

Features

Congress Expands SEC Powers Just In Time for New Administration Image

Congress Expands SEC Powers Just In Time for New Administration

Robert J. Anello & Richard F. Albert

Wall Street has greeted Gary Gensler's nomination as Chair of the SEC with some trepidation, perhaps with good reason. Congress, by contrast, may have presented him with a powerful signing bonus.

Features

NY Proposed Privacy Bill of Rights Could Add to Compliance Confusion Image

NY Proposed Privacy Bill of Rights Could Add to Compliance Confusion

Frank Ready

New York Gov. Andrew Cuomo's executive budget proposal includes plans for a comprehensive data privacy law that rather than bring more clarity to an increasingly fragmented U.S. privacy landscape, could place even more strain on corporate legal departments attempting to get a handle on compliance.

Features

From the PTO to the FDA: What to Consider When Branding Clinical Trials Image

From the PTO to the FDA: What to Consider When Branding Clinical Trials

Brandon Leahy Susanna Lichter & Eva Yin

The legal implications of branding generally arise initially for companies during the process of selecting a company name and any initial product or service names. For drug development companies, however, careful consideration should also be paid to the implications of branding a clinical trial.

Features

The Small Business Reorganization Act: How It Started. How it's Going. Where to Next? Image

The Small Business Reorganization Act: How It Started. How it's Going. Where to Next?

Jack O'Connor

By further expanding access to a streamlined Chapter 11 process, the SBRA will ensure that a wider array of debtors have the ability of reorganizing themselves, when Chapter 11 was previously too cost-prohibitive for such debtors.

Features

Second Circuit Ruling on Personal Benefit Test Widens Scope of Criminal Insider Trading Image

Second Circuit Ruling on Personal Benefit Test Widens Scope of Criminal Insider Trading

Robert J. Anello & Richard F. Albert

The holding in Blaszczak significantly widens the scope of criminal insider trading. It also creates the anomaly of extending the criminal law beyond the SEC's civil enforcement authority.

Features

SCOTUS Set to Address Circuit Split in Interpreting CFAA Image

SCOTUS Set to Address Circuit Split in Interpreting CFAA

Elkan Abramowitz & Jonathan S. Sack 

The Computer Fraud and Abuse Act (CFAA) is the sort of broadly worded criminal statute which gives white-collar prosecutors considerable power — and makes defense counsel and judges uneasy. The meaning of "or exceed[ing] authorized access" is not so clear.

Features

Corporate Compliance Programs and the DOJ's Emphasis on Data Analytics: What Companies Need to Consider Image

Corporate Compliance Programs and the DOJ's Emphasis on Data Analytics: What Companies Need to Consider

Jonathan B. New, Jimmy Fokas, Patrick T. Campbell & Bari R. Nadworny

In recent months, the U.S. Department of Justice has raised expectations for companies to use data analytics to monitor the effectiveness of their compliance programs and to identify potential misconduct.

Need Help?

  1. Prefer an IP authenticated environment? Request a transition or call 800-756-8993.
  2. Need other assistance? email Customer Service or call 1-877-256-2472.

MOST POPULAR STORIES

  • Surveys in Patent Infringement Litigation: The Next Frontier
    Most experienced intellectual property attorneys understand the significant role surveys play in trademark infringement and other Lanham Act cases, but relatively few are likely to have considered the use of such research in patent infringement matters. That could soon change in light of the recent admission of a survey into evidence in <i>Applera Corporation, et al. v. MJ Research, Inc., et al.</i>, No. 3:98cv1201 (D. Conn. Aug. 26, 2005). The survey evidence, which showed that 96% of the defendant's customers used its products to perform a patented process, was admitted as evidence in support of a claim of inducement to infringe. The court admitted the survey into evidence over various objections by the defendant, who had argued that the inducement claim could not be proven without the survey.
    Read More ›
  • In the Spotlight
    On May 9, 2003, the U.S. Attorney's Office for the District of Massachusetts announced that Bayer Corporation, the pharmaceutical manufacturer, had been sentenced and ordered to pay a criminal fine of $5,590,800 stemming from its earlier plea of guilty to violating the Federal Prescription Drug Marketing Act by failing to list with the FDA its drug product, Cipro, that was privately labeled for an HMO. Such listing is required under the federal Food, Drug &amp; Cosmetic Act. The Federal Prescription Drug Marketing Act, Pub. L. 100-293, enacted on April 22, 1988, as modified on August 26, 1992 by the Prescription Drug Amendments (PDA) Pub. L. 102-353, 106 Stat. 941, amended sections 301, 303, 503, and 801 of the Federal Food, Drug, and Cosmetic Act, codified at 21 U.S.C. '' 331, 333, 353, 381, to establish requirements for distributing prescription drug samples.
    Read More ›